Cyclo Therapeutics (CYTH) Reports FY 21 Results, Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Wall Street ends down as oil prices, Treasury yields rise
- Anthropic's Claude AI identifies novel enzyme system in DNA search
- AppLovin (APP) on watch amid 3% drop premarket as boutique comments circulate
- Plug Power COO resigns to join another company
- Xtend AI Robotics wins Phase III of USSOCOM lethal drone program
Cyclo Therapeutics Provides Business Update and Reports Full Year 2021 Financial Results
March 14, 2022 8:05 AM EDT- Lead development program evaluating Trappsol® Cyclo for Niemann-Pick Disease Type C1 (NPC1) in ongoing pivotal study (TransportNPC) continues to progress
- Company advancing Trappsol® Cyclo for the treatment of Alzheimers Disease into Phase 2 study
GAINESVILLE, Fla.--(BUSINESS WIRE)-- Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (Cyclo... More
